Charmi Patel, BS , RN, BSN, MPH

Real-World Outcomes Post-Transition to Once-Every-Three-Month Paliperidone Palmitate in Patients With Schizophrenia Within US Commercial and Managed Care Plans

Background: Medication non-adherence is common for patients with schizophrenia. Decreasing dosing frequency of patients adequately treated with once-monthly paliperidone palmitate (PP1M) ...

Antoine C. El Khoury , PhD;

Bruno Emond , MA;

Maryia Zhdanava , MA;

Kruti Joshi , MPH, MD;

Charmi Patel , BS , RN, BSN, MPH;

Patrick Lefebvre , MA;

Laura Morrison , MPH;

Dominic Pilon , MA;

Neeta Tandon , MA;

03/01/2019

Real World Analysis of Insurance Churn among Young Adult Patients with Schizophrenia Using the Colorado All Payer Claims Database (CO-APCD)

Background Schizophrenia (SCZ) likely leads to changes in and/or loss of employment, which can result in changes to insurance coverage or “churn”. Since patients with schizophrenia are ty...

Charmi Patel , BS , RN, BSN, MPH;

Ravi Potluri ;

David Rotter ;

Carmella Benson , MSc, MS, MSHP;

10/08/2020

Factors Associated With Treatment Initiation With Atypical Long-acting Injectable Antipsychotics Among Medicaid Patients With Schizophrenia

Objectives: Investigate demographic, clinical, and economic factors associated with treatment initiation of paliperidone palmitate (PP) and aripiprazole LAI (ALAI) in Medicaid patients wi...

Antoine C. El Khoury , PhD;

Charmi Patel , BS , RN, BSN, MPH;

Nancy Connolly , MPH;

Edward Kim , MD, MBA;

Qian Cai , MSPH, MS;

Ozgur Tunceli , PhD;

03/01/2019

The Impact of Once-Monthly Paliperidone Palmitate on Healthcare Utilization Among Patients With Schizophrenia Treated in an Integrated Healthcare System

Objective: A previous study demonstrated that patients with schizophrenia consumed substantial healthcare resources in an integrated healthcare system. This study evaluated healthcare uti...

Rohan Mahabaleshwarkar , PhD;

Jesse Fishman , PharmD;

Charmi Patel , BS , RN, BSN, MPH;

Todd Blair ;

Dee Lin , PharmD, MS;

Timothy Hetherington , MS;

Carmella Benson , MSc, MS, MSHP;

Pooja Palmer ;

Kruti Joshi , MPH, MD;

Constance Krull , MSPH;

Oleg Tcheremissine , MD;

10/08/2020

Continuity of Care Among Patients Newly Initiated on Second-Generation Oral or Long-Acting Injectable Antipsychotics During a Schizophrenia-Related Inpatient Stay

Abstract: BACKGROUND: Quality measures were compared between patients initiated on second-generation long-acting injectable antipsychotics (SGLAIs) and oral atypical antipsychotics (OAAs)...

Charmi Patel , BS , RN, BSN, MPH;

Laura Morrison , MPH;

01/19/2023

A Systematic Literature Review of Schizophrenia Clinical Practice Guidelines: Recommendations on use of Long-acting Injectable Anti-psychotic Medications

Background and Objectives: Many clinical practice guidelines (CPGs) on the treatment of schizophrenia have been updated. Aiming to review current CPGs, focusing specifically on long-actin...

Kruti Joshi , MPH, MD;

Edward S. Kim , MD, FACP, MBA;

Christoph U. Correll , MD;

Charmi Patel , BS , RN, BSN, MPH;

Amber Martin , BS;

Rebecca Goulding , PhD;

Jennifer Kern Sliwa , PharmD, BCPP;

Emma Schiller , BA;

Carmella Benson , MSc, MS, MSHP;

10/08/2020

Characteristics of young adults with schizophrenia using Colorado`s All Payer Claims Database (CO-APCD)

Background Schizophrenia (SCZ) is most likely to develop in young adulthood. Using data from a single state, we describe the demographic and clinical characteristics of young adults in t...

Charmi Patel , BS , RN, BSN, MPH;

Ravi Potluri ;

David Rotter ;

Jacqueline Pesa , PhD, MPH;

Eros Papademetriou , MA;

Carmella Benson , MSc, MS, MSHP;

10/08/2020

Risk of Subsequent Relapses and Corresponding Healthcare Costs Among Recently-Relapsed Medicaid Patients With Schizophrenia

BACKGROUND: Schizophrenia relapses can cause a significant increase in healthcare resource utilization and costs. However, the risk of relapse may be different between patients initiated ...

Edward S. Kim , MD, FACP, MBA;

Patrick Lefebvre , MA;

Dee Lin , PharmD, MS;

Kruti Joshi , MPH, MD;

Bruno Emond , MA;

Charmi Patel , BS , RN, BSN, MPH;

Laura Morrison , MPH;

Maria-Helene Lafeuille , MA;

11/22/2019

Prevalence, Incidence and Economic Burden of Schizophrenia Among Medicaid Beneficiaries

Background: Schizophrenia carries a substantial economic burden to healthcare systems and payers. This study aims to update the prevalence, incidence and economic burden of schizophrenia ...

Charmi Patel , BS , RN, BSN, MPH;

Maryia Zhdanava , MA;

Maria-Helene Lafeuille , MA;

Patrick Lefebvre , MA;

Aurélie Côté-Sergent , MSc;

Dominic Pilon , MA;

Dee Lin , PharmD, MS;

Kruti Joshi , MPH, MD;

11/22/2019

Journey of the Veteran Health Administration Population With Recent Schizophrenia Diagnosis: A Real-World Analysis of Treatment Patterns and Healthcare Burden

Background: Schizophrenia is a chronic mental disorder that affects ~0.3-0.7% of the population worldwide and poses a significant economic and societal burden. Objectives: To describe tr...

Charmi Patel , BS , RN, BSN, MPH;

Ahong Huang , BS , MS;

Li Wang , MS, MBA, PhD, MA;

Yoshita Paliwal , PhD;

Kruti Joshi , MPH, MD;

11/22/2019